Clinical trial NCT01714661: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Impaired Cognition
Keywords: Schizophrenia
Cognition
Cognition Impairment
Alpha-7 nAChR
Lead sponsor: FORUM Pharmaceuticals Inc
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
name: NeuroCog Trials, Inc.
First posted: 2012-10-26
Enrollment: 753
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 50 years of age, inclusive
* Signed informed consent, indicating that the subject understands the purpose of and procedures required for the study, before the initiation of any study specific procedures. Subjects who are unable to provide informed consent will not be included in the study.
* Resides in a stable living situation, according to the investigator's judgment, and must have an identified informant who should be consistent throughout the study. If possible, the informant should accompany the subject or be available for in person ratings at the screening, baseline (Day 1), and final study visits. In person informant ratings on all relevant study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview throughout the study at all visits. As long as both the informant visit and subject visit are within the study visit windows, it is not necessary that they occur on the same day. The informant must interact with the subject at least 2 times a week.
* Diagnosis of Schizophrenia of at least 3 years duration. This diagnosis can be established utilizing the SCID-I, direct clinical assessments, family, informants, and confirmation of diagnosis from clinical sources. These may include medical records, confirmation of diagnosis by treating clinician through telephone contact, or written confirmation from treating clinic. If the listed sources are not available, other sources of diagnostic confirmation may also be acceptable after discussion with the medical monitor.
* Treated with atypical antipsychotic drug (in any approved dosage form) other than Clozapine at a stable dose for at least 8 weeks prior to screening and be clinically stable; the subject must remain clinically stable (in the opinion of the principal investigator) through randomization. The use of up to 2 atypical antipsychotic drugs is permitted, as long as in the opinion of the investigator, the second medication is not required to control treatment-resistant or intractable psychotic symptoms. No subject will be washed off antipsychotic therapy to become eligible for this study.
* Schizophrenia clinical symptom burden severity defined by the following: a Brief Psychiatric Rating Scale (BPRS) Conceptual Disorganization item score ≤ 4; and a BPRS Hallucinatory Behavior item score ≤ 5, or an Unusual Thought Content item score ≤ 5. Either Hallucinatory Behavior or Unusual Thought Content, but not both, may have a score of 6 (but not \> 6).
* Simpson-Angus Scale (SAS) total score ≤ 6
* Calgary Depression Scale for Schizophrenia (CDSS) total score ≤ 10
* General health status acceptable for participation in a 26-week clinical study
* Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study
* Fluency (oral and written) in the language in which the standardized tests will be administered
* The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing

Exclusion Criteria:

* Hospitalization within 12 weeks before screening or during the screening period, or change of antipsychotic medication or dose within 8 weeks before screening or during the screening period.
* Participation in another therapeutic (medication administration) clinical study within the past 2 months.
* Psychiatric hospitalization or incarcerations due to breakthrough symptoms or acute exacerbations for a period of 3 months before screening. Subjects with a recent "social" hospitalization or incarceration may be entered into screening after consultation with the medical monitor
* Likelihood, in the opinion of the investigator, that either the subject or informant will be unable to complete a 26-week study
* Treatment with prohibited antipsychotic drug, and/or treatment with more than 2 permitted antipsychotic drugs. Treatment with a first-generation antipsychotic drug (typical antipsychotic) is prohibited unless it is administered at a low dose after discussion with the medical monitor
* Current treatment with any anticholinergic agent
* Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria met for alcohol abuse within the past 3 months or substance abuse (other than nicotine) within the last 6 months before screening
* Significant suicide risk as defined by 1) suicidal ideation as endorsed on items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year; 2) suicidal behavior detected by the C-SSRS during the past 2 years, or 3) psychiatric interview and examination
* Stroke within 6 months before screening, history of brain tumor, subdural hematoma, or other clinically significant neurological condition, head trauma with loss of consciousness within 12 months before screening
* Monoamine oxidase inhibitor antidepressants or tricyclic medications used in antidepressant doses are excluded. Other antidepressant medications are allowed if the subject has been treated with a stable dose for at least 3 months before screening
* Immunosuppressants, mood stabilizers, chronic use of a sedative hypnotic drug, chronic intake of clinically significant doses of opioid containing analgesics or any current methadone treatment all in the judgment of the investigator may be permitted depending on the circumstance
* Use of Central Nervous System(CNS) stimulants
* Nicotine therapy (including patches), varenicline (Chantix), or similar therapeutic agent within the last six months before screening
* Use of a benzodiazepine medication is allowed if the subject has not had a change in medication or dose for at least 3 months. For subjects prescribed benzodiazepines, short-acting benzodiazepines are to be used whenever possible. Use of longer-acting benzodiazepines may be acceptable if prior authorization is obtained from the medical monitor. When possible, benzodiazepines should not be administered within 3 hours before cognitive testing. The use of more than one sedative-hypnotic medication is not allowed.

Primary outcomes:
measure: Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182
timeFrame: Baseline to Day 182 or Early Terminiation
measure: Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia
timeFrame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation
Secondary outcomes:
measure: Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
measure: Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182
timeFrame: Baseline to Day 182 or Early Termination
Other outcomes:
Locations:
city: Tucson
country: United States
state: Arizona
city: Anaheim
country: United States
state: California
city: Bellflower
country: United States
state: California
city: Costa Mesa
country: United States
state: California
city: Culver City
country: United States
state: California
city: Downey
country: United States
state: California
city: Escondido
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Oceanside
country: United States
state: California
city: Orange
country: United States
state: California
city: San Diego
country: United States
state: California
city: Torrance
country: United States
state: California
city: Lauderhill
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: North Miami
country: United States
state: Florida
city: Orange City
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Wichita
country: United States
state: Kansas
city: Shreveport
country: United States
state: Louisiana
city: Minneapolis
country: United States
state: Minnesota
city: Flowood
country: United States
state: Mississippi
city: Creve Coeur
country: United States
state: Missouri
city: O'Fallon
country: United States
state: Missouri
city: St. Louis
country: United States
state: Missouri
city: Omaha
country: United States
state: Nebraska
city: Marlton
country: United States
state: New Jersey
city: Albuquerque
country: United States
state: New Mexico
city: Cedarhurst
country: United States
state: New York
city: New York
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Durham
country: United States
state: North Carolina
city: Cleveland
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Conshohocken
country: United States
state: Pennsylvania
city: Norristown
country: United States
state: Pennsylvania
city: Philadelphia
country: United States
state: Pennsylvania
city: Dallas
country: United States
state: Texas
city: La Plata
country: Argentina
state: Buenos Aires
city: Caba
country: Argentina
city: Cordoba
country: Argentina
city: Mendoza
country: Argentina
city: Melbourne
country: Australia
city: Itapira
country: Brazil
state: SP
city: Rio de Janeiro
country: Brazil
city: Sao Paulo
country: Brazil
city: Calgary
country: Canada
state: Alberta
city: Penticton
country: Canada
state: British Columbia
city: Chatham
country: Canada
state: Ontario
city: Kingston
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
city: Achim
country: Germany
city: Berlin
country: Germany
city: Dusseldorf
country: Germany
city: Freiburg
country: Germany
city: Leipzig
country: Germany
city: Mittweida
country: Germany
city: Munchen
country: Germany
city: Regebsburg
country: Germany
city: Regensburg
country: Germany
city: Stralsund
country: Germany
city: Wiesbaden
country: Germany
city: Mexico
country: Mexico
state: D.F
city: Guadalajara
country: Mexico
state: Jalisco
city: Monterrey
country: Mexico
state: Neuvo Leon
city: Bialystok
country: Poland
city: Gdansk
country: Poland
city: Lodz
country: Poland
city: Lublin
country: Poland
city: Torun
country: Poland
city: Tuszyn
country: Poland
city: Warszawa
country: Poland
city: Talagi
country: Russian Federation
state: Arkangelsk region
city: Moscow
country: Russian Federation
city: Saint-Petersburg
country: Russian Federation
city: Stavropol
country: Russian Federation
city: Belgrade
country: Serbia
city: Kragujevac
country: Serbia
city: Nis
country: Serbia
city: Novi Knezevac
country: Serbia
city: Singapore
country: Singapore
city: Mataro
country: Spain
state: Barcelona
city: Salamanca
country: Spain
state: Castilla y Leon
city: Zamora
country: Spain
state: Castilla y Leon
city: Alcorcon
country: Spain
state: Madrid
city: Coslada
country: Spain
state: Madrid
city: Vigo
country: Spain
state: Pontevedra
city: Barcelona
country: Spain
city: Madrid
country: Spain
city: Donetsk
country: Ukraine
city: Ivano-Frankivsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kyiv
country: Ukraine
city: Lugansk
country: Ukraine
Study officials:
References: